Research Analysts Issue Forecasts for AbbVie FY2027 Earnings

AbbVie Inc. (NYSE:ABBV) – Equities research analysts at Erste Group Bank reduced their FY2027 earnings per share (EPS) estimates for shares of AbbVie in a report issued on Wednesday, August 5th. Erste Group Bank analyst H. Engel now anticipates that the company will earn $16.24 per share for the year, down from their previous forecast of $16.40. Erste Group Bank currently has a “Buy” rating on the stock. The consensus estimate for AbbVie’s current full-year earnings is $14.07 per share.

Several other research firms also recently issued reports on ABBV. Royal Bank Of Canada upped their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Piper Sandler reissued an “overweight” rating and issued a $298.00 price target on shares of AbbVie in a research note on Tuesday, June 23rd. Barclays increased their target price on shares of AbbVie from $275.00 to $300.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Morgan Stanley reiterated an “overweight” rating and set a $296.00 price objective on shares of AbbVie in a research report on Monday, August 3rd. Finally, Canaccord Genuity Group lifted their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $275.70.

AbbVie Stock Performance

Shares of ABBV opened at $247.86 on Tuesday. The stock has a market capitalization of $437.92 billion, a price-to-earnings ratio of 70.02, a PEG ratio of 0.82 and a beta of 0.30. AbbVie has a 52 week low of $190.75 and a 52 week high of $267.47. The stock has a fifty day moving average of $242.67 and a 200-day moving average of $225.28.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Wednesday, July 15th. AbbVie’s payout ratio is presently 195.48%.

Institutional Investors Weigh In On AbbVie

A number of large investors have recently bought and sold shares of the stock. Litman Gregory Wealth Management LLC bought a new position in shares of AbbVie during the 4th quarter worth about $28,000. Imprint Wealth LLC increased its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares in the last quarter. IFC & Insurance Marketing Inc. acquired a new position in AbbVie during the 4th quarter worth approximately $31,000. Legacy Wealth Managment LLC ID boosted its holdings in AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock worth $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its holdings in AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Botox gained a potential new indication: The FDA accepted AbbVie’s supplemental application for Botox Cosmetic to treat masseter muscle prominence, bringing the product closer to a fifth use. Approval would expand Botox’s addressable market and support additional aesthetics revenue. AbbVie’s Botox Just Got a Step Closer to a Fifth Use
• Positive Sentiment: Apogee strengthens AbbVie’s immunology pipeline: The proposed $10.9 billion acquisition adds zumilokibart, which produced positive Phase 2 results in atopic dermatitis and is expected to advance into Phase 3. The drug also has potential applications in asthma and eosinophilic esophagitis, helping AbbVie diversify beyond Humira and bolster its long-term immunology growth. AbbVie to Acquire Apogee Therapeutics for $10.9 Billion
• Neutral Sentiment: Analyst sentiment remains favorable: Brokerages hold a consensus “Moderate Buy” rating, while recent commentary viewed AbbVie as potentially undervalued after strong second-quarter earnings. However, the shares already trade near their 52-week high and at a high earnings multiple, which may limit immediate upside. AbbVie Receives Consensus Rating of Moderate Buy
• Negative Sentiment: Debt-funded acquisition is the key concern: AbbVie is reportedly taking on approximately $8 billion of debt for the Apogee deal. While the acquisition could replace revenue lost to patent expirations, higher leverage may increase interest costs and raise questions about capital allocation and the sustainability of AbbVie’s dividend. The transaction still requires customary regulatory and shareholder approvals. AbbVie Piles on $8 Billion in Debt for Its Apogee Deal

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.